Last reviewed · How we verify
Ostenil plus
At a glance
| Generic name | Ostenil plus |
|---|---|
| Sponsor | TRB Chemedica |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis
- Routine Application of Ostenil® in Patients with Gonarthrosis
- Routine Application of Ostenil® Mini in Patients with Rhizarthrosis
- Comparing Injection Treatments for Tennis Elbow (NA)
- Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis (PHASE4)
- Clinical Investigation to Compare the Safety and Efficacy of Cellular Matrix to Those of Ostenil® Plus and to Those of PRP Only (NA)
- Gait Analysis Following Knee Viscosupplementation (PHASE2, PHASE3)
- Efficacy of OSTENIL PLUS (Hyaluronic Acid) Versus SYNVISC-ONE in Patients With Tibiofemoral Osteoarthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ostenil plus CI brief — competitive landscape report
- Ostenil plus updates RSS · CI watch RSS
- TRB Chemedica portfolio CI